These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22907123)

  • 1. Long-term lanreotide treatment in six patients with congenital hyperinsulinism.
    Kühnen P; Marquard J; Ernert A; Meissner T; Raile K; Wannenmacher G; Blankenstein O
    Horm Res Paediatr; 2012; 78(2):106-12. PubMed ID: 22907123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.
    Corda H; Kummer S; Welters A; Teig N; Klee D; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2017 Jun; 12(1):108. PubMed ID: 28576129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact.
    Shah P; Rahman SA; McElroy S; Gilbert C; Morgan K; Hinchey L; Senniappan S; Levy H; Amin R; Hussain K
    Horm Res Paediatr; 2015; 84(5):355-60. PubMed ID: 26375451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.
    van der Steen I; van Albada ME; Mohnike K; Christesen HT; Empting S; Salomon-Estebanez M; Greve Rasmussen A; Verrijn Stuart A; van der Linde AAA; Banerjee I; Boot AM
    Horm Res Paediatr; 2018; 89(2):82-89. PubMed ID: 29241206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia.
    Dastamani A; Güemes M; Pitfield C; Morgan K; Rajab M; Rottenburger C; Bomanji J; De Coppi P; Dattani M; Shah P
    Horm Res Paediatr; 2019; 91(1):56-61. PubMed ID: 30114684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.
    Welters A; Lerch C; Kummer S; Marquard J; Salgin B; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2015 Nov; 10():150. PubMed ID: 26608306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy.
    Giri D; Price V; Yung Z; Didi M; Senniappan S
    J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):347-50. PubMed ID: 27087264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
    Modan-Moses D; Koren I; Mazor-Aronovitch K; Pinhas-Hamiel O; Landau H
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2312-7. PubMed ID: 21697252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.
    Cuff H; Lord K; Ballester L; Scully T; Stewart N; De Leon DD
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3115-e3120. PubMed ID: 35587448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review.
    Ertorer ME; Bakiner O; Anaforoglu I; Bozkirli E; Tutuncu NB; Demirag NG
    Neuro Endocrinol Lett; 2007 Dec; 28(6):727-33. PubMed ID: 18063933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.
    Antonijoan RM; Barbanoj MJ; Cordero JA; Peraire C; Obach R; Vallès J; Chérif-Cheikh R; Torres ML; Bismuth F; Montes M
    J Pharm Pharmacol; 2004 Apr; 56(4):471-6. PubMed ID: 15099442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of long-acting somatostatin analogs in congenital hyperinsulinism].
    Novokreshhennyx EE; Gubaeva DN; Melikyan MA
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):70-78. PubMed ID: 33369374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
    Hosokawa Y; Kawakita R; Yokoya S; Ogata T; Ozono K; Arisaka O; Hasegawa Y; Kusuda S; Masue M; Nishibori H; Sairenchi T; Yorifuji T
    Endocr J; 2017 Sep; 64(9):867-880. PubMed ID: 28701683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.